Clinical Edge

Summaries of Must-Read Clinical Literature, Guidelines, and FDA Actions

In recurrent ovarian cancer, secondary surgery does not extend survival

Key clinical point: Secondary surgical cytoreduction did not extend overall survival among women with platinum-sensitive, recurrent ovarian cancer.

Major finding: The adjusted hazard ratio for death was 1.29 (95% confidence interval, 0.97-1.72; P = .08) for surgery, compared with no surgery. Median overall survival times were 50.6 months in the surgery arm and 64.7 months in the no-surgery arm.

Study details: Newly reported results from the GOG-0213 study included 485 women with platinum-sensitive recurrent ovarian cancer randomized to receive cytoreduction prior to chemotherapy or chemotherapy alone.

Disclosures: First author Robert L. Coleman, MD, reported disclosures related to several pharmaceutical companies, including Agenus, AstraZeneca, Clovis, GamaMabs, Genmab, Janssen, Medivation, Merck, Regeneron, Roche/Genentech, OncoQuest, and Tesaro.


Coleman RL et al. N Engl J Med. 2019;381:1929-39.